Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)

Trial Profile

Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2022

At a glance

  • Drugs CK 0802 (Primary)
  • Indications Adult respiratory distress syndrome; COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RESOLVE
  • Sponsors Cellenkos
  • Most Recent Events

    • 08 Mar 2022 Status changed from active, no longer recruiting to completed.
    • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 04 Nov 2021 According to a Cellenkos media release, the results will be presented during an oral presentation at the annual meeting of the ASH.

Trial Overview

Purpose

This Phase I, placebo-controlled study is designed to assess the safety and preliminary efficacy of cryopreserved cord blood-derived T-regulatory cells (CK0802) for treatment of COVID-19 associated acute respiratory distress syndrome (hospitalized patient population).

Primary Endpoints

Regimen related ≥ grade 3 toxicity within 48 hours of first infusion

description: Regimen related ≥ grade 3 toxicity within 48 hours of first infusion (DLT)
time_frame: 48 hours

28-day treatment success, defined as S28 [ Time Frame: 28 days]

Alive and not intubated 28 days after the date of first infusion

Other Endpoints

Time to extubation

description: Time to extubation
time_frame: 28 days

Oxygenation improvement

description: Oxygenation requirement (PaO2/FiO2) change between day 0 and day +11
time_frame: 11 days

Ventilator free days

description: Ventilator free days measured at day 28
time_frame: 28 days

Organ failure free days

description: Organ failure free days measured at day 28
time_frame: 28 days

ICU free days

description: ICU free days measured at day 28
time_frame: 28 days

All-cause mortality

description: All-cause mortality at day 28
time_frame: 28 days [1]

Diseases Treated

Indication Qualifiers Patient Segments
Adult respiratory distress syndrome treatment -
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Number

    Planned: 45

    Actual: 45

  • Sex male & female
  • Age Group 21-85(median 60) years; adult; elderly

Patient Inclusion Criteria

- Documented to have an RT-PCR-based diagnosis of SARS-CoV-2 infection by RT-PCR - Moderate-to-severe ARDS as defined by the Berlin Criteria: ratio of partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) of 200 mm Hg or less assessed with a positive end-expiratory pressure (PEEP) of >5 cm H2O. - Intubated for less than 120 hours - Age ≥18 years - Ability to provide informed consent or duly appointment health care proxy with the authority to provide informed consent.

Patient Exclusion Criteria

1. In the opinion of the investigator, unlikely to survive for >48 hours from screening. 2. Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study. 3. Currently receiving extracorporeal membrane oxygenation (ECMO) or high frequency oscillatory ventilation (HFOV). 4. Females who are pregnant. 5. Patients with active bacteremia at start of therapy enrollment or concurrently active moderate to severe other infectious which in the opinion of the investigator may possibly affect the safety of CK0802 treatment. 6. Patients who have been intubated for more than 120 hours. 7. Known hypersensitivity to DMSO or to porcine or bovine protein. 8. Any end-stage organ disease which in the opinion of the investigator may possibly affect the safety of CK0802 treatment. 9. High dose steroids. 10. Receiving an investigational cellular therapy agent.

Trial Details

Identifiers

Identifier Owner
NCT04468971 ClinicalTrials.gov: US National Institutes of Health
CK0802-501-1 -

Organisations

  • Sponsors Cellenkos
  • Affiliations Cellenkos

Trial Dates

  • Initiation Dates

    Planned : 30 Aug 2020

    Actual : 29 Sep 2020

  • Primary Completion Dates

    Planned : 30 Sep 2021

    Actual : 22 Oct 2021

  • End Dates

    Planned : 30 Sep 2021

    Actual : 22 Oct 2021

Other Details

  • Design double-blind; multicentre; parallel; prospective; randomised
  • Phase of Trial Phase I
  • Location USA
  • Focus Adverse reactions; Therapeutic Use

Interventions

Drugs Route Formulation
CK 0802Primary Drug Intravenous Infusion

Arm 2

CK0802: 1x10^8 cells
Biological: CK0802 (Cryopreserved, off the shelf, cord blood derived T regulatory cells)

Arm 3

CK0802: 3x10^8 cells
Biological: CK0802 (Cryopreserved, off the shelf, cord blood derived T regulatory cells)

Arm 1

Excipient
Drug: Placebo (Expicient)

Results

Therapeutic efficacy

In the phase I RESOLVE trial, treatment with CK 0802 showed promising efficacy. Median time to extubation from first infusion was 10.5 [2-46] days and median ventilator free days at day 28 was 12 [0-26]days. Time to extubation from first infusion was 10.5 days (2-46) and at day 28 the ventilator free days were 12 (0-26). The estimated day 28 overall survival was 78.6% with the following breakdown according to the co-variates: i) age>60 yrs =77.5% vs. age<60yrs=79.9%; ii) female=85.7% vs male=73.7%; iii) on vasopressor=65.8% vs. 77.8%; iv) on hemodialysis=75% vs. 79%. Duration of intubation to enrollment had no impact on 28d survival. At baseline, 14 patients were positive for both HLA I and HLA II antibodies (Abs); 3 patients positive for HLA I Ab only, and 9 positive for HLA II Ab only. In 20 paired samples collected on day 0 and day 28, HLA I Ab and HLA II Ab seroconversion was observed in 4 and 1 patient, respectively [2] .

Adverse events

In the phase I RESOLVE trial, treatment with CK 0802 was found to be safe. No treatment related SAEs were reported [2] .

Publications

  1. Gladstone DE, Howard C, Lyu M-A, Mock J, Adams D, Gibbs K, et al. Randomized, Multi-Center, Double-Blinded, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) in the Treatment of COVID-19 Induced ARDS. (RESOLVE Trial). ASH-Hem-2021 2021; abstr. 828.

    Available from: URL: https://ash.confex.com/ash/2021/webprogram/Paper153616.html

Authors

Author Total Publications First Author Last Author
Adams D 1 - -
D'Alessio F 1 - -
Gibbs K 1 - -
Gladstone DE 1 1 -
Hari P 1 - -
Herlihy J 1 - -
Howard C 1 - -
Huang M 1 - -
Li L 1 - -
Lyu M-A 1 - -
Mock J 1 - -
Mukherjee S 1 - 1
Parmar S 1 - -
Sadeghi T 1 - -
Slutsky A 1 - -
Trevino S 1 - -
Zeng K 1 - -

Trial Centres

Investigators

Investigator Centre Name Trial Centre Country
Carlos Reyes-Vidal
212-305-4921 csr52@cumc.columbia.edu
show details
Columbia University USA
Christopher Howard, MD Baylor College of Medicine, St Luke's Hospital USA
Darryl Adams Columbia University USA
Douglas Gladstone, MD Johns Hopkins Hospital USA
Jason Mock, MD, PhD University of North Carolina USA
Joby Mathew
jmathe27@jhmi.edu
show details
Johns Hopkins Hospital USA
Kevin Harris Wake Forest University USA
Pinchie Onyango
336-716-6591 ponyango@wakehealth.edu
show details
Wake Forest University USA
Rafael Cardenas
Rafael.CardenasCastillo@bcm.edu
show details
Baylor College of Medicine, St Luke's Hospital USA
Tara Sadeghi
7138064787
tara.sadeghi@cellenkosinc.com
show details
, Cellenkos Inc.
-

Centres

Centre Name Location Trial Centre Country
-
-
-
Baylor College of Medicine, St Luke's Hospital Houston, Texas USA
Cellenkos Inc.
-
-
Columbia University New York, New York USA
Johns Hopkins Hospital Baltimore, Maryland USA
University of North Carolina Chapel Hill, North Carolina USA
Wake Forest University Winston-Salem, North Carolina USA

Trial History

Event Date Event Type Comment
14 Mar 2022 Other trial event Last checked against ClinicalTrials.gov record. Updated 14 Mar 2022
08 Mar 2022 Status change - completed Status changed from active, no longer recruiting to completed. Updated 14 Mar 2022
14 Dec 2021 Results Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition Updated 27 Jan 2022
04 Nov 2021 Other trial event According to a Cellenkos media release, the results will be presented during an oral presentation at the annual meeting of the ASH. Updated 16 Nov 2021
21 Jun 2021 Status change - active, no longer recruiting Status changed from recruiting to active, no longer recruiting. Updated 24 Jun 2021
29 Sep 2020 Status change - recruiting Status changed from not yet recruiting to recruiting. Updated 05 Oct 2020
16 Jul 2020 Other trial event New source identified and integrated:(ClinicalTrials.gov: US National Institutes of Health: NCT04468971). Updated 16 Jul 2020
10 Jul 2020 Status change - not yet recruiting Status changed from planning to not yet recruiting. Updated 16 Jul 2020
06 Jul 2020 Other trial event According to a Cellenkos media release, this trial is anticipated to start in the third quarter of 2020. Updated 08 Jul 2020
02 Jun 2020 Other trial event According to a Cellenkos media release, Dr Siddhartha Mukherjee (MD, PhD, Columbia University, New York) is the scientific advisor and collaborator on this multi-center clinical trial.According to him planned correlative assays during the clinical trial will provide insights into the mechanism of action of CK0802 and its relation to clinical outcomes. Updated 08 Jun 2020
02 Jun 2020 Other trial event According to a Cellenkos media release, the US Food and Drug Administration (FDA) has cleared the way to initiate this Phase 1 clinical trial of CK0802 (Cryopreserved Cord Blood Derived T-Regulatory Cells) for treatment of COVID-19 associated acute respiratory distress syndrome (ARDS). Updated 08 Jun 2020
18 Mar 2020 New trial record New trial record Updated 18 Mar 2020
17 Mar 2020 Other trial event According to a Cellenkos media release, the company has submitted a clinical development proposal to the Biomedical Advanced Research and Development Authority (BARDA) to start this study. Updated 18 Mar 2020

References

  1. ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2023;.

    Available from: URL: http://clinicaltrials.gov
  2. Gladstone DE, Howard C, Lyu M-A, Mock J, Adams D, Gibbs K, et al. Randomized, Multi-Center, Double-Blinded, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) in the Treatment of COVID-19 Induced ARDS. (RESOLVE Trial). ASH-Hem-2021 2021; abstr. 828.

    Available from: URL: https://ash.confex.com/ash/2021/webprogram/Paper153616.html
  3. Cellenkos. Cellenkos(R) Inc. Announces FDA Clearance to Initiate Phase 1 Double- Blinded, Randomized, Placebo-Controlled Trial of Cryopreserved Cord Blood-Derived T-Regulatory Cells (CK0802) for Treatment of COVID-19 Associated Acute Respiratory Distress Syndrome. Media-Rel 2020;.

    Media Release
  4. Johns Hopkins University. Johns Hopkins Reports Promising Clinical Data in COVID-19 ARDS Treated with Cellenkos' Cord Blood T-Regulatory Cells. Media-Rel 2020;.

    Media Release
  5. Cellenkos. Cellenkos Inc. Focuses on the Development of Cell-Therapy for Treatment of COVID-19 Mediated Acute Respiratory Distress Syndrome (CoV-ARDS). Media-Rel 2020;.

    Media Release
  6. Cellenkos. Cellenkos(Rm) Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based Therapies. Media-Rel 2021;.

    Media Release
Back to top